Cargando…

Methodological Issues on a Clinical Trial to Test Tapentadol Prolonged release vs. Oxycodone/Naloxone Prolonged release

Detalles Bibliográficos
Autores principales:	Bacallao, Jorge, Casado, Alfonso J., Baron, Ralf, Steigerwald, Ilona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4806565/ https://www.ncbi.nlm.nih.gov/pubmed/26936316 http://dx.doi.org/10.1111/papr.12435

Ejemplares similares

Pain therapy with oxycodone/naloxone prolonged-release combination: case report
por: Błaszczyk, Feliks, et al.
Publicado: (2013)

Intractable restless legs syndrome: role of prolonged-release oxycodone–naloxone
por: de Biase, Stefano, et al.
Publicado: (2016)

Combatting pain after orthopedic/trauma surgery- perioperative oral extended-release tapentadol vs. extended-release oxycodone/naloxone
por: Haeseler, Gertrud, et al.
Publicado: (2017)

Effectiveness and safety of tapentadol prolonged release with tapentadol immediate release on-demand for the management of severe, chronic osteoarthritis-related knee pain: results of an open-label, phase 3b study
por: Steigerwald, Ilona, et al.
Publicado: (2012)

Colorectal Transit and Volume During Treatment With Prolonged-release Oxycodone/Naloxone Versus Oxycodone Plus Macrogol 3350
por: Poulsen, Jakob L, et al.
Publicado: (2018)

Effectiveness and Tolerability of Tapentadol Prolonged Release Compared With Prior Opioid Therapy for the Management of Severe, Chronic Osteoarthritis Pain
por: Steigerwald, Ilona, et al.
Publicado: (2013)

Tapentadol Prolonged Release: A Review in Pain Management
por: Deeks, Emma D.
Publicado: (2018)

Correction to: Tapentadol Prolonged Release: A Review in Pain Management
por: Deeks, Emma D.
Publicado: (2019)

Tapentadol Prolonged Release for Long-Term Treatment of Pain in Children
por: Howard, Richard F, et al.
Publicado: (2020)

Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain
por: Sandner-Kiesling, A, et al.
Publicado: (2010)

Efficacy and tolerability of low-dose oral prolonged-release oxycodone/naloxone for chronic nononcological pain in older patients
por: Guerriero, Fabio, et al.
Publicado: (2014)

Analgesic Efficacy and Safety of Prolonged-Release Oxycodone/Naloxone in Korean Patients with Chronic Pain from Spinal Disorders
por: Hwang, Chang Ju, et al.
Publicado: (2018)

Sex Differences in Oxycodone/Naloxone vs. Tapentadol in Chronic Non-Cancer Pain: An Observational Real-World Study
por: Barrachina, Jordi, et al.
Publicado: (2022)

Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain
por: Ahmedzai, Sam H., et al.
Publicado: (2014)

A phase III randomized controlled study on the efficacy and improved bowel function of prolonged‐release (PR) oxycodone‐naloxone (up to 160/80 mg daily) vs oxycodone PR
por: Dupoiron, D., et al.
Publicado: (2017)

ENhANCE trial protocol: A multi-centre, randomised, phase IV trial comparing the efficacy of oxycodone/naloxone prolonged release (OXN PR) versus oxycodone prolonged release (Oxy PR) tablets in patients with advanced cancer
por: Wong, Aaron K., et al.
Publicado: (2022)

Tapentadol vs oxycodone/naloxone in the management of pain after total hip arthroplasty in the fast track setting: an observational study
por: D’Amato, Tiziana, et al.
Publicado: (2019)

Driving Ability in Patients with Severe Chronic Low Back or Osteoarthritis Knee Pain on Stable Treatment with Tapentadol Prolonged Release: A Multicenter, Open-label, Phase 3b Trial
por: Sabatowski, Rainer, et al.
Publicado: (2014)

Cancer pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: results from a non-interventional study
por: Nolte, Thomas, et al.
Publicado: (2013)

Low-dose oral prolonged-release oxycodone/naloxone for chronic pain in elderly patients with cognitive impairment: an efficacy–tolerability pilot study
por: Petrò, Emiliano, et al.
Publicado: (2016)

Prolonged-release oxycodone/naloxone reduces opioid-induced constipation and improves quality of life in laxative-refractory patients: results of an observational study
por: Bantel, Carsten, et al.
Publicado: (2018)

Lasting Prolonged-Release Tapentadol for Moderate/Severe Non-Cancer Musculoskeletal Chronic Pain
por: Samolsky Dekel, Boaz G., et al.
Publicado: (2015)

Tapentadol and Oxycodone/Naloxone Prescribing Patterns in Primary Health Care in Catalonia, Spain: A Cross-Sectional Study
por: Viñas-Bastart, Montserrat, et al.
Publicado: (2021)

Oxycodone/naloxone versus tapentadol in real-world chronic non-cancer pain management: an observational and pharmacogenetic study
por: Barrachina, Jordi, et al.
Publicado: (2022)

Prolonged-Release (PR) Oxycodone/Naloxone Improves Bowel Function Compared with Oxycodone PR and Provides Effective Analgesia in Chinese Patients with Non-malignant Pain: A Randomized, Double-Blind Trial
por: Leng, Xiaomei, et al.
Publicado: (2020)

Developments in managing severe chronic pain: role of oxycodone–naloxone extended release
por: Fanelli, Guido, et al.
Publicado: (2015)

A comparison between the administration of oral prolonged-release oxycodone-naloxone and transdermal fentanyl in patients with moderate-to-severe cancer pain: a propensity score analysis
por: Roberto, A, et al.
Publicado: (2017)

Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial
por: Lee, Kyung-Hee, et al.
Publicado: (2017)

Tapentadol prolonged release for severe chronic cancer-related pain: effectiveness, tolerability, and influence on quality of life of the patients
por: Schikowski, Artur, et al.
Publicado: (2014)

Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour‐related pain
por: Kress, H.G., et al.
Publicado: (2016)

Bioavailability of oxycodone after administration of a new prolonged-release once-daily tablet formulation in healthy subjects, in comparison to an established twice-daily tablet
por: Scheidel, Bernhard, et al.
Publicado: (2017)

Long-term evaluation of combined prolonged-release oxycodone and naloxone in patients with moderate-to-severe chronic pain: pooled analysis of extension phases of two Phase III trials
por: Blagden, M, et al.
Publicado: (2014)

Switching to low-dose oral prolonged-release oxycodone/naloxone from WHO-Step I drugs in elderly patients with chronic pain at high risk of early opioid discontinuation
por: Lazzari, Marzia, et al.
Publicado: (2016)

Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease
por: Coluzzi, Flaminia, et al.
Publicado: (2015)

Tapentadol Prolonged Release Reduces the Severe Chronic Ischaemic Pain and Improves the Quality of Life in Patients with Type 2 Diabetes
por: Tedeschi, Anna, et al.
Publicado: (2018)

Tapentadol Prolonged Release for Severe Chronic Osteoarthritis Pain in the Elderly—A Subgroup Analysis of Routine Clinical Practice Data
por: Schwittay, Andreas, et al.
Publicado: (2020)

Long-term efficacy and safety of oxycodone–naloxone prolonged release in geriatric patients with moderate-to-severe chronic noncancer pain: a 52-week open-label extension phase study
por: Guerriero, Fabio, et al.
Publicado: (2016)

A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain
por: Ahmedzai, Sam H, et al.
Publicado: (2012)

Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials
por: Löwenstein, Oliver, et al.
Publicado: (2010)

Sleep and Quality of Life Under Prolonged Release Oxycodone/Naloxone for Severe Restless Legs Syndrome: An Analysis of Secondary Efficacy Variables of a Double-Blind, Randomized, Placebo-Controlled Study with an Open-Label Extension
por: Oertel, Wolfgang H., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1cbqtc746tmatodvmvn2cemae2